北京健康年报2024

Incorporated in the Cayman Islands with limited liabilityStock Code: 2389 Annual Report2024 Contents目錄 60Independent Auditor’s Report67Consolidated Statement of Profit orLoss and Other Comprehensive Income70Consolidated Statement of FinancialPosition72Consolidated Statement of Changes inEquity74Consolidated Statement of Cash Flows77Notes to Financial Statements200Particulars of Properties 8Management Discussion and Analysis 23Corporate Governance Report 41Directors and Senior Management Corporate Information公司資料 As at 31 December 2024 BOARD OF DIRECTORSExecutive Directors Mr. Zhu Shi Xing(Chairman)Mr. Liu Xue Heng(Chief Executive Officer)Mr. Siu Kin WaiMr. Gu Shan ChaoMr. Hu Shiang Chi (Resigned on 29 February 2024)Mr. Wang Zheng Chun Independent Non-executive Directors Mr. Gary Zhao (Resigned on 29 February 2024)Mr. Robert Winslow Koepp (Resigned on 29 February 2024)Mr. Tse Man Kit, KeithMr. Wu Yong XinMr. Zhang Yun ZhouMs. Yang Xiao Yan (Appointed on 2 December 2024) AUTHORISED REPRESENTATIVES Mr. Lam Ka TakMr. Liu Xue Heng COMPANY SECRETARYMr. Lam Ka Tak AUDIT COMMITTEE Mr. Tse Man Kit, Keith(Chairman of the committee)Mr. Gary Zhao (Resigned on 29 February 2024)Mr. Wu Yong XinMr. Zhang Yun Zhou (Appointed on 29 February 2024)Ms. Yang Xiao Yan (Appointed on 2 December 2024) REMUNERATION COMMITTEE Mr. Zhang Yun Zhou(Chairman of the committee)(Appointed on 29 February 2024)Mr. Gary Zhao (Resigned on 29 February 2024)Mr. Tse Man Kit, KeithMr. Wu Yong XinMs. Yang Xiao Yan (Appointed on 2 December 2024) NOMINATION COMMITTEE Mr. Wu Yong Xin(Chairman of the committee)Mr. Gary Zhao (Resigned on 29 February 2024)Mr. Tse Man Kit, KeithMr. Zhu Shi XingMr. Zhang Yun Zhou (Appointed on 29 February 2024)Ms. Yang Xiao Yan (Appointed on 2 December 2024) INVESTMENT AND RISK MANAGEMENT COMMITTEE Mr. Gu Shan Chao(Chairman of the committee)Mr. Liu Xue HengMr. Zhu Shi XingMr. Lam Ka Tak Corporate Information • As at 31 December 2024 AUDITORS Ernst & YoungCertified Public AccountantsRegistered Public Interest Entity Auditor LEGAL ADVISERDLA PiperGuanto Law Firm 2389 STOCK CODE2389 www.bjhl.com.hk WEBSITEwww.bjhl.com.hk PRINCIPAL BANKERS Bank of BeijingChina Citic Bank InternationalShanghai Pudong Development Bank REGISTERED OFFICE Cricket SquareHutchins DriveP.O. Box 2681, KY1-1111Grand CaymanCayman Islands Cricket SquareHutchins DriveP.O. Box 2681, KY1-1111Grand CaymanCayman Islands 909272704 HEAD OFFICE AND PRINCIPAL PLACE OF BUSINESS Unit 2704, 27/F909 Cheung Sha Wan RoadCheung Sha WanKowloon, Hong Kong PRINCIPAL SHARE REGISTRAR AND TRANSFEROFFICE Suntera (Cayman) LimitedSuite 3204, Unit 2A, Block 3Building D, P.O. Box 1586Gardenia Court, Camana BayGrand Cayman, KY1-1110Cayman Islands Suntera (Cayman) LimitedSuite 3204, Unit 2A, Block 3Building D, P.O. Box 1586Gardenia Court, Camana BayGrand Cayman, KY1-1110Cayman Islands HONG KONG BRANCH SHARE REGISTRAR ANDTRANSFER OFFICE 3382333301–04 Union Registrars LimitedSuites 3301–04, 33/FTwo Chinachem Exchange Square338 King’s RoadNorth PointHong Kong Corporate Structure公司架構 Financial Summary財務摘要 Chairman’s Statement主席報告 Dear Shareholders, I am pleased to present the results for the year ended 31 December2024 (the “Year”) of Beijing Health (Holdings) Limited (the “Company”)and its subsidiaries (collectively, the “Group”) to the shareholders of theCompany (the “Shareholders”). REVIEW OF RESULTS 115,575,00061,721,000149,945,0006.8%1.963.1 In 2024, the Group’s loss for the Year increased to HK$115,575,000(2023: HK$61,721,000), and the consolidated revenue was approximatelyHK$149,945,000, representing an increase of 6.8% as compared to thecorresponding period in 2023. As at 31 December 2024, cash and cashequivalents and other rapidly realisable investments (mainly referringto financial products of banks) amounted to approximately HK$196million (31 December 2024: HK$310 million). In line with the Group’slongstanding prudent practice, there were no interest-bearing liabilitiesin 2024. BUSINESS REVIEW In 2024, the Group continued to focus on the development of the greaterhealthcare industry, with geriatric care business, health industrial parksbusiness and sales business of medical and geriatric products as thecore. Geriatric Care Business 61,243484914,038,00072%500 By the end of 2024, the Group operated 6 geriatric care institutionswith a total of 1,243 geriatric beds, which included 849 medical bedsprovided by 4 medical institutions. During the Year, revenue related togeriatric care business amounted to approximately HK$14,038,000. Theaverage occupancy rate of the Group’s geriatric care institutions wasapproximately 72%. Each geriatric care institution has achieved a break-even position and continued to provide positive cash flow for the Group.The Group will accelerate the development of its geriatric care businessand expects to increase the number of beds by 500 in the coming year. Health Industrial Park Business In respect o